Market Cap 453.56M
Revenue (ttm) 160.18M
Net Income (ttm) -69.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -43.33%
Debt to Equity Ratio -0.79
Volume 3,103,200
Avg Vol 3,701,964
Day's Range N/A - N/A
Shares Out 236.23M
Stochastic %K 26%
Beta 0.95
Analysts Strong Sell
Price Target $7.38

Latest News on AKBA

Akebia Therapeutics Announces Multiple Positive Business Updates

Jan 13, 2025, 8:00 AM EST - 2 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates


Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 20, 2024, 3:31 PM EST - 4 months ago

Q3 2024 Earnings: Hold Akebia Therapeutics


Akebia Therapeutics to Present at Upcoming Investor Conferences

Aug 26, 2024, 8:00 AM EDT - 7 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences


Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript

May 9, 2024, 10:54 AM EDT - 11 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript


U.S. FDA approves Akebia's anemia drug

Mar 27, 2024, 8:45 PM EDT - 1 year ago

U.S. FDA approves Akebia's anemia drug


Akebia Secures $55 Million Term Loan Financing

Jan 30, 2024, 8:00 AM EST - 1 year ago

Akebia Secures $55 Million Term Loan Financing


Akebia Therapeutics: Waiting For Round 2

Nov 3, 2023, 5:52 PM EDT - 1 year ago

Akebia Therapeutics: Waiting For Round 2